Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Table 2—EMG Results During Illness*

| Muscle         | Insertional Activity | Fibrillations and PSW | Fasciculations | Recruitment | Motor Unit Potentials |
|----------------|----------------------|-----------------------|----------------|-------------|-----------------------|
| Right deltoid  | Increased            | 1+                    | 0              | Normal      | 50–75% PPMUP, large units |
| Right biceps   | Increased            | 3+                    | 0              | Decreased   | 75% PPMUP, large units  |
| Right EDC      | Increased            | 3+                    | 0              | Normal      | 75% PPMUP, large units  |
| Right 1st DI   | Increased            | 3+                    | 0              | None        | No MUPS               |
| Right APB      | Increased            | 3+                    | 0              | Decreased   | 50–75% PPMUP, large units |
| Right vastus L | Increased            | 3+                    | 0              | Decreased   | 50–75% PPMUP, large units |
| Right tib ant  | Increased            | 3+                    | 0              | Decreased   | 50–75% PPMUP, large units |
| Right med gastroc | Increased      | 3+                    | 0              | Decreased   | 50–75% PPMUP, large units |
| Right intercostals | Increased | 3+                    | 0              | Decreased   | 50–75% PPMUP, large units |
| Right sternocleid | Increased         | 3+                    | 0              | Decreased   | 50–75% PPMUP, large units |

*EDC = extensor digitorum communis; DI = dorsal interosseus; APB = abductor pollicis brevis; L = lateralis; tib ant = tibialis anterior; med gastroc = medial gastrocnemius; sternocleid = sternocleidomastoid; PPMUP = polyphasic motor unit potential.

Results of her neurologic examination had normalized with 5/5 strength of proximal and distal muscle groups, resolved wasting, and normal reflexes. Sensation continued to normal. At last follow-up 1 year after initial hospital admission, she was asymptomatic, without recurrence of her hypernephroma.

Discussion

In the medical literature, motor neuronopathies have rarely been associated with solid tumors. In a recent review, Forsyth et al. described 14 patients with motor neuron disease and cancer. These were grouped into patients having anti-Hu antibodies, patients with either a lower motor neuron (LMN) or upper motor neuron (UMN) form, or patients with more typical combined UMN and LMN findings. The authors suggested that patients with either specific paraneoplastic markers (e.g., anti-Hu) or with an isolated UMN or LMN syndrome should be investigated for an underlying cancer. In this series, one patient with small cell lung cancer had improvement in muscular weakness with chemotherapy early in his clinical course. Two patients developed respiratory failure late in their disease course requiring mechanical ventilation. No patient presented with respiratory failure or was able to be weaned from mechanical ventilation after therapy for the tumor.

To our knowledge, this is the first reported case of a paraneoplastic motor neuron disease (MND) presenting with respiratory failure. Furthermore, there was a complete recovery of motor strength and successful weaning from ventilator support following removal of the underlying malignancy. There are case reports of patients with MND having remission of neurologic symptoms after successful removal of their tumor. Renal cell carcinoma in association with MND has been reported, but presenting with more typical peripheral motor weakness. Resolution or improvement of symptoms followed removal of the renal tumor. Such cases are presumably autoantibody related with resolution of antibody production after tumor removal.

In patients with unexplained neuromuscular respiratory failure, the differential diagnosis should include a reversible paraneoplastic motor neuronopathy. Neurologic investigation and EMG/nerv conduction studies should be sought early in such patients.

References

1. Younger DS, Rowland LP, Latov N, et al. Lymphoma, motor neuron diseases, and amyotrophic lateral sclerosis. Ann Neurol 1991; 29:78–86
2. Forsyth PA, Dalmau J, Graus F, et al. Motor neuron syndromes in cancer patients. Ann Neurol 1997; 41:722–730
3. Buchanan DS, Malamud N. Motor neuron diseases with renal cell carcinoma and postoperative neurologic remission: a clinicopathologic report. Neurology 1973; 23:891–894
4. Mitchell M, Olfzak A. Remission of a syndrome indistinguishable from motor neuron disease after resection of bronchial carcinoma. BMJ 1979; 2:176–177
5. Evans BK, Fagan C, Arnold T, et al. Paraneoplastic motor neuron disease and renal cell carcinoma: improvement after nephrectomy. Neurology 1990; 40:960–962

Coronavirus Pneumonia Following Autologous Bone Marrow Transplantation for Breast Cancer*

Rodney J. Folz, MD, PhD; and Maha A. Elkordy, MD

Infectious bronchitis virus, otherwise known as coronavirus, can cause mild upper respiratory tract illnesses in children and adults. Rarely has coronavirus been linked, either by serology or nasal wash, to pneumonia. We report a case of a young woman who, following treatment for stage IIIA breast cancer using a high-dose chemotherapy regimen followed by autologous bone marrow and stem cell transplantation, developed respiratory failure and was found to have coronavirus pneumonia as diagnosed by electron microscopy from BAL fluid. We propose that coronavirus should be considered in the differential diagnosis of acute respiratory failure in cancer patients who have undergone high-dose chemotherapy and autologous hematopoietic support.

*CHEST 1999; 115:901–905

Key words: bone marrow transplantation; breast cancer; coronavirus pneumonia; high-dose chemotherapy; idiopathic pneumonia syndrome
Interstitial pneumonia is a frequent complication following high-dose chemotherapy and autologous bone marrow transplantation (HD/CABMT).

Infections have been identified in about 50% of cases and include cytomegalovirus (CMV), herpes simplex virus, respiratory syncytial virus (RSV), Pneumocystis carinii, adenovirus, Aspergillus, and Candida. In the remaining cases in which no infectious agents could be identified, several distinct syndromes have been described. Idiopathic pneumonia syndrome (IPS) is the most severe form of posttransplant interstitial pneumonitis and is best characterized by severe hypoxemia, radiographic infiltrates, and is associated with high mortality. However, we have recently described in detail a milder form of posttransplant pneumonitis occurring in autologous bone marrow transplant (BMT) patients that we have termed delayed pulmonary toxicity syndrome (DPTS). DPTS is characterized by its high incidence (69%), prompt response to steroids with resolution of pulmonary symptoms and improvement in diffusion of carbon monoxide (DLCO), and very low mortality. Radiographic abnormalities, when present, typically appear as scattered, predominantly peripheral ill-defined opacities.

Possible mechanisms for the pathogenesis of either IPS or DPTS include the following: (1) pulmonary drug toxic reactions caused by carbamustine (BCNU) and/or cyclophosphamide; (2) imbalance of lung cytokines that promote a proinflammatory state; (3) occult latent viral infections (eg, CMV, RSV, Epstein-Barr virus, or human herpes 6 virus); (4) an imbalance in pulmonary oxidants and antioxidants; (5) Allogeneic transplant patients, in contrast to autologous, are also susceptible to graft-vs-host disease processes and in addition, are maintained in an immunodeficient state for an extended time.

The coronaviruses are one of the more recently identified major families of viruses that have been associated with the development of the common cold. They are a family of positive-sense single-stranded RNA viruses with distinctive club-shape projections imparting a crown or corona-shaped appearance. OC43 and 229E are two major serologic subtypes. They are a major serologic coronavirus strains identified to be important in human disease. Only indirectly has coronavirus been linked to lower respiratory tract infections.

In this report, we document the development of acute respiratory failure following BMT that was atypical of either IPS or DPTS and that, we believe, was caused or exacerbated by coronavirus pneumonia. To our knowledge, this represents the first reported case of coronavirus isolated from lower respiratory tract specimens in an adult with pneumonia.

**Case Report**

A 35-year-old Jamaican woman, 155 days post HD/CABMT for stage IIIA breast carcinoma, was admitted to Duke University Hospital with complaints of fatigue, anorexia, and weight loss and for further workup of hyperbilirubinemia.

The patient had been well until 13 months prior to hospital admission when a left breast mass was noted on self-examination. An incisional biopsy specimen with subsequent modified radical mastectomy revealed an infiltrating ductal carcinoma with 14/15 lymph nodes positive for metastatic tumor. A staging chest/abdomen/pelvis/head CT and bone scan revealed no metastatic disease. Results of initial laboratory studies, including liver function tests, were normal. Baseline pulmonary function testing demonstrated an FEV\(_1\) of 2.27 L (76%), FVC of 2.79 L (80%), total lung capacity of 3.46 L (71%), and a hemoglobin-corrected DLCO of 28.5 mL/min/mm Hg (133%).

The patient was enrolled on the Cancer and Leukemia Group B protocol 9092. She received four cycles of CAB (cyclophosphamide, 600 mg/m\(^2\) on day 1, doxorubicin, 60 mg/m\(^2\) on day 1, and fluorouracil, 600 mg/m\(^2\) on days 1 and 8) given every 28 days (Fig 1) that was followed by high-dose CPA/CDDP/BCNU (cyclophosphamide [1.875 mg/m\(^2\)], cisplatin [55 mg/m\(^2\)] given by continuous infusion over 24 h each day for 3 consecutive days (day −6, −5, −4), cisplatin [55 mg/m\(^2\)] by continuous infusion over 24 h each day for 3 consecutive days (day −6, −5, −4, and −3), and BCNU [600 mg/m\(^2\)] infused over 2 h on day −3). The total plasma area under the curve for cyclophosphamide was 93,280 µg/mL × min. Cisplatin levels were determined at the end of each 24-h dose and were 112.4, 62.8, and 121.6 µg/mL. The BCNU plasma area under the curve was 607.5 µg/mL × min. Two days following high-dose chemotherapy, peripheral blood progenitor cells were reinjected (days −1, 0, +1) and autologous bone marrow (0.7 ± 0.25 × 10\(^8\) cells per kilogram of body weight) was reinjected on day +1 to provide cellular support.

Engraftment was uneventful and occurred by 2 weeks. Thirty-eight days post-BMT, the patient developed over the course of 2 days, a nonproductive cough and dyspnea. An arterial blood gas determination performed on room air showed a pH of 7.45, P\(_{CO_2}\) of 36 mm Hg, P\(_O_2\) of 89 mm Hg, and O\(_2\) saturation of 98%. Pulmonary function testing at this time showed that her DLCO had fallen 54% from her baseline level (Fig 1). Based on these findings, she was diagnosed as having DPTS and was started on a regimen of oral prednisone at 60 mg/d. In addition, prophylactic oral trimethoprim/sulfamethoxazole was prescribed. She responded to prednisone treatment with prompt resolution of her pulmonary symptoms and a modest improvement of 11% in her DLCO.

At 83 days post-BMT, routine blood testing demonstrated mildly elevated results of liver function tests. At 91 days, her chest wall and regional node radiation therapy was begun and continued over 6 weeks for a total dose of 60.4 Gy.

At 157 days post-BMT, the patient was admitted to the hospital for workup of persistent hyperbilirubinemia. Perianal ulcer biopsy specimens demonstrated severe, centriflobular cholestasis with plugs in canaliculi consistent with centrilobular canicular and hepatocellular cholestasis. This was believed to be consistent with an idiosyncratic drug reaction. Later that evening, she developed a brief episode of hypotension and complained of right shoulder pain. Abdominal CT demonstrated a small right subcapsular hematoma at the site of the liver biopsy. On hospital day 3, the patient spiked a fever with a temperature of 38.9°C. Blood and urine cultures were sent to the laboratory and the patient was
started on a regimen of oral clarithromycin. At about this time, she complained of a sore throat and a new cough, slightly productive of sputum. A nasal swab was negative for RSV, parainfluenza A, B, and C, adenovirus, and influenza A and B. Results of pulmonary function testing were unchanged from 13 days previously (Fig 1).

On hospital day 4, the patient was noted to be tachypneic with a respiratory rate in the 40s. An arterial blood gas determination obtained on room air showed a pH of 7.46, $P_{CO_2}$ of 25, $P_{O_2}$ of 36, and O$_2$ saturation of 70%. An echocardiogram demonstrated normal ventricular function. Despite a 3-L diuresis, the patient’s respiratory status continued to deteriorate and she was electively intubated. Because of concerns of recurrent DPTS, the patient was started on a regimen of high-dose methylprednisolone at 60 mg IV every 6 h. Erythromycin, sulfamethoxazole and trimethoprim (Bactrim), and imipenem were added empirically. A portable chest radiograph and chest CT scan demonstrated bilateral, predominantly lower lobe air space opacities (Fig 2).

On hospital day 6, the patient underwent bronchoscopy and a BAL of both lower lobes was obtained via the endotracheal tube. Microbiological examination demonstrated the BAL sample to be negative for fungus, acid-fast bacilli, Gram stain and culture, cytology with special stains, respiratory viral battery (RSV, parainfluenza A, B, and C, adenovirus, and influenza A and B), CMV, and herpes simplex virus culture. Cytologic analysis showed rare atypical cells on a background of highly reactive pneumocytes. Electron microscopy (EM) of the BAL fluid demonstrated numerous viral particles with features that were diagnostic of coronavirus (Fig 3).

On hospital day 7, treatment with all antibiotics was stopped and the patient had completely defervesced. On hospital day 8, the patient was successfully extubated. By hospital day 10, she was breathing room air with oxygen saturation of 96%. Her steroids were changed to prednisone at 60 mg to be tapered over 6 to 8 weeks. On hospital day 12, she was discharged to home. By hospital day 10, she was breathing room air with oxygen saturation of 96%. Her steroids were changed to prednisone at 60 mg to be tapered over 6 to 8 weeks. On hospital day 12, she was discharged to home. Her respiratory status remained asymptomatic.

Discussion

The incidence of pulmonary toxic reactions following high doses of cyclophosphamide/cisplatin and BCNU with autologous bone marrow support in the Duke University Bone Marrow Transplant Program is approximately 39 to 69%.6,7,21 Most patients in whom infection is ruled out have a low mortality rate and a prompt response to prednisone therapy. Because of these features, we have termed this posttransplant complication DPTS.6 DPTS is to be contrasted to IPS, a syndrome characterized by severe hypoxemia, radiographic infiltrates, and high mortality.4

Our patient demonstrated three phases of pulmonary toxic reactions. Phase I is subclinical and asymptomatic and is best characterized by a decreased $DLCO$ measurement following the first three cycles of the CAF induction chemotherapy (Fig 1). Little is known about the contribution that the conditioning regimen plays in the development of lung injury.

Phase II occurred following HDC/ABMT and was diagnosed as DPTS based on its timing, associated pulmonary symptoms, decrease in $DLCO$, and prompt response to corticosteroid therapy with subsequent improvement in $DLCO$.

Phase III occurred approximately 158 days following BMT when the patient developed acute respiratory failure. Was coronavirus pneumonia responsible for her respiratory failure? We believe so. The BAL sample was obtained 36 h after intubation and the bronchoscope was placed into the lumen of the endotracheal tube, thus minimizing possible nasal mucosa contamination. We have considered other possibilities. For example, the coronavirus could simply have been present in the BAL specimen, but was not pathogenic. In this scenario, the etiology of the respiratory failure could have been caused by several different factors, including radiation pneumonitis, drug-induced interstitial pneumonitis, or showering of the lung with inflammatory cytokines from an abdominal or septic source resulting in ARDS. Radiation pneumonitis seems less likely since the pattern of radiographic lung injury does not duplicate the radiation port,5 although case studies have shown that radiation pneumonitis can occur.
outside the radiation port. It would be unusual to see interstitial pneumonitis from the HDC/ABMT this far out after transplant and without a concomitant decrease in DLCO. The liver biopsy, which occurred 2 days before respiratory failure, was complicated by a stable subcapsular hematoma, a brief episode of hypotension, and fever. We cannot exclude the possibility that inflammatory cytokines, released from GI sources, showered the lung causing acute lung injury leading to respiratory failure. Also, we could not rule out bacterial pneumonia as a complicating factor since the patient was receiving antibiotics for >24 h prior to obtaining BAL fluid and this would be predicted to lower our diagnostic yield of bacteria.

Can coronavirus cause lower respiratory tract infection? Animal strains of coronavirus appear more virulent than their human counterparts and have been shown to cause pneumonia in mice and pigs. In humans, experimental intranasal inoculation of coronavirus in volunteers results in a typical coryzal illness with nasal discharge and a notable absence of systemic complaints. However, lower respiratory tract involvement has been suggested based on coronavirus positive nasal washes in two children with pneumonia and by coronavirus seroconversion in adults who had pneumonia. Treatment options for upper respiratory tract infection caused by coronavirus are limited, but studies using intranasal interferon and intranasal nedocromil improve symptoms.

In this report, we document coronavirus pneumonia complicating autologous BMT. Whether coronavirus pneumonia is capable by itself of causing respiratory failure or if it requires additional factors (eg, immunocompromised host) remains to be determined. Our patient’s condition initially improved with institution of corticosteroids but longer-term follow-up showed some deterioration in lung function, leaving us to wonder if coronavirus causes direct cytopathologic effects in lower respiratory airway cells.

We discovered coronavirus in this patient because the...
References

1. Weiner RS, Boyner MM, Gale RP, et al. Interstitial pneumonitis after bone marrow transplantation. Ann Intern Med 1986; 104:168–175.
2. Wingard JR, Mellits ED, Sostrin MB, et al. Interstitial pneumonitis after allogeneic bone marrow transplantation. Medicine 1989; 67:175–186.
3. Jones RB, Matthes S, Sapall EJ, et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carbustine: pharmacodynamic evaluation of carbustine. J Natl Cancer Inst 1993; 85:640–647.
4. Clark JG, Hansen JA, Hertz MI, et al. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993; 147:1601–1606.
5. Cherniack RM, Abrams J, Kalica AR. Pulmonary disease associated with breast cancer therapy. Am J Respir Crit Care Med 1994; 150:1169–1173.
6. Wilczynski SW, Erasmus JJ, Petros WP, et al. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. Am J Respir Crit Care Med 1998; 157:565–573.
7. Wilczynski SW, Petros WP, Hussein AM, et al. Increased incidence of pulmonary toxicity in breast cancer patients undergoing high dose chemotherapy. Am J Respir Crit Care Med 1996; 153:A273.
8. Patz EF Jr, Peters WP, Goodman PC. Pulmonary drug toxicity following high-dose chemotherapy with autologous bone marrow transplantation: CT findings in 20 cases. J Thorac Imaging 1994; 9:129–134.
9. Aroin PA, Mahaley MS Jr, Rudnick SA, et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas. N Engl J Med 1980; 303:183–188.
10. Rabinowitz J, Petros WP, Stuart AR, et al. Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support. Blood 1993; 81:2452–2459.
11. Murase T, Anschel MS, Petros WP, et al. Changes in plasma transforming growth factor beta in response to high-dose chemotherapy for stage II breast cancer: possible implications for the prevention of hepatic veno-occlusive disease and pulmonary drug toxicity. Bone Marrow Transplant 1994; 15:173–178.
12. Englund JA, Sullivan C, Jordan MC, et al. Respiratory syncytial virus infection in immunocompromised adults. Ann Int Med 1988; 109:203–208.

13. Fouillard L, Mounlon L, Laporte JP, et al. Sever respiratory syncytial virus pneumonia after autologous bone marrow transplantation: a report of three cases and review. Bone Marrow Transplant 1992; 9:97–100.
14. Smith AC, Boyd MR. Preferential effects of 1,3-bis(2-chloroethyl)-1-nitrosurea (BCNU) on pulmonary glutathione reductase and glutathione/glutathione disulfide ratios: possible implications for lung toxicity. J Pharmacol Exp Ther 1984; 229:658–663.
15. Kaye HS, Marsh HB, Dowdle WR. Seroprevalence logic survey of coronavirus (strain OC43) related infections in a children's population. Am J Epidemiol 1971; 94:43–49.
16. Hendley JO, Fishburne HB, Gwaltney JM. Coronavirus infections in working adults: eight year study with 229E and OC43. Am Rev Respir Dis 1972; 105:805–811.
17. Hamre D, Beem M. Virologic studies of acute respiratory disease in young adults. V. Coronavirus 229E infections during 6 years of surveillance. Am J Epidemiol 1972; 96:94–106.
18. McIntosh K, Chao RK, Krause HE, et al. Coronavirus infection in acute lower respiratory tract disease of infants. J Infect Dis 1974; 130:502–507.
19. Wenzel RP, Hendley JO, Davies JA, et al. Coronavirus infections in military recruits. Am Rev Respir Dis 1974; 109:621–624.
20. Riski H, Hovi T. Coronavirus infections of man associated with diseases other than the common cold. J Med Virol 1980; 6:259–265.
21. Todd NW, Peters WP, Ost AH, et al. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis 1993; 147:1250–1270.
22. Fulkerson WJ, McLeod RE, Frosnitz LR. Adult respiratory distress syndrome after limited thoracic radiotherapy. Cancer 1986; 57:1941–1946.
23. Bhatt FN, Jacoby R, Jonas AM. Respiratory infection in mice with sialodacryoadenitis virus, a coronavirus of rats. Infect Immun 1977; 20:823–827.
24. Barbana A, Girard C, Elzahary Y. Pathogenicity of porcine respiratory coronavirus isolated in Quebec. Can Vet J 1994; 35:56–92.
25. Bradburne AF, Bynoe ML, Tyrrell DAJ. Effects of a ‘new’ human respiratory virus in volunteers. BMJ 1967; 3:767–769.
26. Reed SE. The behavior of recent isolates of human respiratory coronavirus in vitro and in volunteers: evidence of heterogeneity among 229E-related strains. J Med Virol 1984; 13:179–192.
27. Bende M, Barrow I, Heptonstall J, et al. Changes in human nasal mucosa during experimental coronavirus common colds. Acta Otolaryngol (Stockh) 1989; 107:263–269.
28. Higgins PG, Phillpotts RJ, Scott GM, et al. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob Agents Chemother 1983; 24:713–715.
29. Turner RB, Felton A, Kossak K, et al. Prevention of experimental coronavirus colds with intranasal α-2b interferon. J Infect Dis 1986; 154:443–447.
30. Barrow GI, Higgins PG, Al-Nakib W, et al. The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers. Clin Exp Allergy 1990; 20:45–51.
31. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Am J Respir Crit Care Med 1995; 152:2185–2198.